patient 1[6] patient 2 [7] patient 3[8] present patient age/sex 15 / F late 30s / F 42 / F 45 / F initial symptoms phychosis phychosis phychosis phychosis other clinical features         involuntary movements ＋ ＋ ＋ ＋ autonomic instability ＋ ＋ - ＋ seizures - - - ＋ ventilatory support ＋ ＋ ＋ ＋ tumor - ovary teratoma ovary teratoma - cranial MRI normal progressive atrophy normal normal therapies         first-line immune treatments - ST, IVIG, PE ST, IVIG ST, IVIG, PE second-line immune treatments - rituximab, cyclophosphamide - - tumor resection - ＋ ＋ - first hospital stay 5 yr 25 mo 25 mo 4 yr disease condition at first hospital discharge learning impairments dead cognitive impairments GCS 9 anti-NMDAR antibodies titers       first examination         serum 1: 1000*a 1: 102400 ＋*b 1: 1600 CSF 1: 320*a 1: 10240 ＋*b 1: 320 CSF cells 29 /mm3*a 237 NA*b 13 /mm3 final follow-up examination 15 yr 16 mo 4 yr 4 yr disease conditions no symptoms comatose with hyperkinetic movements mild cognitive impairments GCS 9 serum 1: 320 1: 25600 ＋ 1: 200 CSF 1: 32 1: 5120 ND 1: 80 CSF cells 1 /mm3 NA NA 0 /mm3

Table 1: Long-term follow-up (>2 years) of anti-N-methyl-D-aspartate receptor (NMDAR) antibody titers in previous patients with anti- NMDAR encephalitis who did not have recurrence